Novartis India Ltd
Novartis India Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Guidance rank: #29 of 84 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
2 of 3 strong
The short version
The company aims to double its revenues over the next 4 to 5 years from the current base. Near-term profitability expected to dip due to upfront costs related to the commercial reset and Minipress acquisition, including hiring and acquisition costs.
From Novartis India Ltd's Q1 FY27 earnings-call transcript · updated 18 Sept 2026.
Revenue & Sales Performance
- The company aims to double its revenues over the next 4 to 5 years from the current base.
- Growth will be driven by organic expansion as well as potential M&A opportunities.
- Focused growth in six core therapy areas: cardiology, pain management, women's health, CNS, transplant, and ophthalmology, which contribute 40-50% of incremental market value annually.
- Expansion of sales force from approximately 900 MRs, with hiring completed by end of Q3 and full productivity expected from Q4 onward.
- Utilizing lifecycle management strategies and new product introductions within focus therapy areas to drive growth.
- Expansion of distribution network from 4 to 25 C&Fs to cover tier 2 and tier 3 towns for better market penetration.
2 more points from Novartis India Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Novartis India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capital deployment focus will be on marketing, promotion, and acquiring brands rather than manufacturing.
- A disciplined capital deployment approach is emphasized to maximize returns.
- The company has recently acquired the Minipress XL trademark from Pfizer and an ophthalmology portfolio via in-licensing from NHPL.
- M&A will be an integral part of growth strategy, with careful financial prudence and strict filters applied before pursuing any acquisition.
- Incremental costs of INR 40-50 crores per quarter are expected due to team-building, marketing, and commercial reset.
2 more points from Novartis India Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Novartis India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Novartis India Ltd said on order book & pipeline — free account, 30 seconds.
Novartis India Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹91 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjiv.Parant. (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Novartis India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Novartis India Ltd Q1 FY27 results?
The company aims to double its revenues over the next 4 to 5 years from the current base. Near-term profitability expected to dip due to upfront costs related to the commercial reset and Minipress acquisition, including hiring and acquisition costs.
What is Novartis India Ltd share price analysis?
Novartis India Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 60.4 with a market cap of ₹5,904 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Novartis India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.